Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evaxion A (EVAX) Research & Development (2022 - 2026)

Evaxion A filings provide 5 years of Research & Development readings, the most recent being -$2.3 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 6.59% to -$2.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$10.1 million, a 3.45% decrease, with the full-year FY2025 number at -$10.0 million, up 4.61% from a year prior.
  • Research & Development hit -$2.3 million in Q1 2026 for Evaxion A, up from -$2.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.8 million in Q1 2022 to a low of -$4.1 million in Q4 2022.
  • Median Research & Development over the past 5 years was -$2.6 million (2025), compared with a mean of -$1.5 million.
  • The widest YoY moves for Research & Development: up 43.58% in 2023, down 180.18% in 2023.
  • Evaxion A's Research & Development stood at -$4.1 million in 2022, then surged by 43.58% to -$2.3 million in 2023, then grew by 1.87% to -$2.3 million in 2024, then decreased by 13.48% to -$2.6 million in 2025, then rose by 10.2% to -$2.3 million in 2026.
  • The last three reported values for Research & Development were -$2.3 million (Q1 2026), -$2.6 million (Q4 2025), and -$3.1 million (Q3 2025) per Business Quant data.